Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Relationship between body mass index and prostate cancer screening in the United States.

Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P, Moul JW.

J Urol. 2007 Feb;177(2):493-8.

PMID:
17222617
2.

The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.

Culp S, Porter M.

BJU Int. 2009 Nov;104(10):1457-61. doi: 10.1111/j.1464-410X.2009.08646.x. Epub 2009 Jun 12.

3.

Prostate-specific antigen screening among young men in the United States.

Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW.

Cancer. 2008 Sep 15;113(6):1315-23. doi: 10.1002/cncr.23667.

4.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

5.

The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.

Pruthi RS, Swords K, Schultz H, Carson CC 3rd, Wallen EM.

J Urol. 2009 Feb;181(2):574-7; discussion 578. doi: 10.1016/j.juro.2008.10.028. Epub 2008 Dec 13.

PMID:
19084847
6.

Barriers to the initiation and maintenance of prostate specific antigen screening in Black American and Afro-Caribbean men.

Gonzalez JR, Consedine NS, McKiernan JM, Spencer BA.

J Urol. 2008 Dec;180(6):2403-8; discussion 2408. doi: 10.1016/j.juro.2008.08.031. Epub 2008 Oct 18.

PMID:
18930293
7.

The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.

Paranhos M, Antunes A, Andrade E, Freire G, Srougi M.

BJU Int. 2009 Oct;104(8):1130-3. doi: 10.1111/j.1464-410X.2009.08562.x. Epub 2009 May 5.

8.

Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.

Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ.

Urology. 2008 May;71(5):787-91. doi: 10.1016/j.urology.2007.11.036. Epub 2008 Feb 11.

PMID:
18267334
9.

Body mass index and cancer screening in older American Indian and Alaska Native men.

Muus KJ, Baker-Demaray T, McDonald LR, Ludtke RL, Allery AJ, Bogart TA, Goldberg J, Ramsey SD, Buchwald DS.

J Rural Health. 2009 Winter;25(1):104-8. doi: 10.1111/j.1748-0361.2009.00206.x.

PMID:
19166569
10.

Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.

Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ.

J Urol. 2008 Apr;179(4):1340-3. doi: 10.1016/j.juro.2007.11.068. Epub 2008 Mar 4.

PMID:
18289590
11.

Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.

Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR.

J Urol. 2005 Mar;173(3):732-6.

12.
13.

Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men.

Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR.

J Urol. 2007 Nov;178(5):1939-44; discussion 1945. Epub 2007 Sep 17.

PMID:
17868722
14.

Overweight, obesity, and colorectal cancer screening: disparity between men and women.

Heo M, Allison DB, Fontaine KR.

BMC Public Health. 2004 Nov 8;4:53.

15.

Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.

Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, Suardi N, Saad F, BĂ©nard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI.

Eur J Cancer. 2007 May;43(7):1180-7. Epub 2007 Feb 9.

PMID:
17292604
16.

Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL Jr; PLCO Project Team..

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):748-51. doi: 10.1158/1055-9965.EPI-08-0938. Epub 2009 Mar 3.

17.

Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.

Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK.

J Urol. 2006 Feb;175(2):500-4; discussion 504.

PMID:
16406980
18.

Prostate specific antigen mass ratio potential as a prostate cancer screening tool.

Choi HC, Park JH, Cho BL, Son KY, Kwon HT.

J Urol. 2010 Aug;184(2):488-93. doi: 10.1016/j.juro.2010.03.138. Epub 2010 Jun 17.

PMID:
20620404
19.
20.

Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.

McDavid K, Melnik TA, Derderian H.

Prev Med. 2000 Sep;31(3):195-202.

PMID:
10964632

Supplemental Content

Support Center